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Background: It is increasingly evident that patients with chronic kidney disease (CKD) are more 
likely to die from heart disease than kidney failure. This study evaluated whether  pre-dialysis 
CKD is an independent risk factor for coronary artery calcium (CAC).
Methods: A total of 544 consecutive patients who underwent CAC scoring were analyzed. 
Eleven patients requiring hemodialysis were excluded. Patients were divided into three groups: 
normal glomerular filtration rate (GFR) (GFR . 90 mL/min/1.73 m2), mild CKD (90 $ 
GFR . 60 mL/min/1.73 m2), and moderate CKD (60 $ GFR . 30 mL/min/1.73 m2).  Continuous 
and categorical variables were compared using analysis of variance and the χ2 statistic. A multiple 
logistic regression model was used for detecting the association between total CAC score and 
GFR. An unadjusted model was used, followed by a second model adjusted for covariates known 
to be related to CAC. Another multivariable binary logistic model predicting the presence of 
CAC (.10) was performed and odds of incidence of CAC (.10) were calculated among the 
three GFR subgroups.
Results: After adjustment for covariates, patients with mild CKD had mean CAC scores 
175 points higher than those with the referent normal GFR (P = 0.048), while those with 
moderate CKD had mean CAC scores 693 points higher than the referent (P , 0.001). After 
adjustment for covariates, patients with mild CKD were found to be 2.2 times more likely (95% 
confidence interval 1.3–3.7, P = 0.004) and patients with moderate CKD were 6.4 times more 
likely (95% confidence interval 2.9–14.3, P , 0.001) to have incident CAC compared with 
the group with normal GFR.
Conclusion: Mild and moderate pre-dialysis CKD are independent risk factors for increased 
mean and incident CAC.
Keywords: kidney disease, coronary artery disease, atherosclerosis, calcium
Background
Chronic kidney disease (CKD) has been shown to be an independent risk factor for 
cardiovascular events and it has become increasingly evident that patients with CKD 
are more likely to die from cardiovascular disease than kidney failure.1 Coronary 
artery calcium (CAC) score is a marker for atherosclerotic plaque burden and has 
been shown to be a predictor of incidence of myocardial infarction and death from 
cardiovascular disease.2 Numerous studies have identified an association between 
end-stage renal disease and CAC,2–4 but a link between pre-dialysis CKD and 
increased CAC has not been clearly established. CKD should lead to increased CAC 
scores secondary to accelerated progression of atherosclerosis,1 as well as changes 
in  calcium homeostasis.4
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CKD results in accelerated progression of atherosclerosis 
for many reasons. CKD has been shown to cause both hyper-
tension and dyslipidemia, which are known risk factors for 
coronary artery disease (CAD).5 It causes an increase in blood 
pressure because of plasma volume expansion, retention of 
sodium, increased sympathetic activity, increased renin–
angiotensin–aldosterone axis activity, and the accumulation 
of endogenous vasoactive substances.6 Additionally, there 
is clear evidence that CKD results in increased LDL and 
triglycerides, as well as decreased HDL.7
Atherosclerosis is an inflammatory condition, as well, 
and CRP, a marker of systemic inflammation, has been shown 
to be a surrogate for atherosclerosis and treatment.8 CKD 
results in increased CRP levels,9 which is evidence that CKD 
results in the increased systemic inflammation associated 
with atherosclerosis. CKD also alters calcium and phospho-
rous homeostasis, resulting in increased phosphorous and 
parathyroid hormone, as well as decreased vitamin D levels. 
All of this contributes to vascular calcification, including 
coronary artery calcification.10 Finally, CKD also results 
in increased lipoprotein A,11 increased homocysteine,12 and 
anemia,13 all of which have been associated with CAD.6 
The authors of this paper sought to evaluate whether pre-
dialysis CKD is an independent risk factor for increased 
CAC score.
Methods
study subjects
A total of 544 consecutive patients referred to the authors’ 
center (Harbor-UCLA Medical Center) who underwent 
multidetector computed tomography for CAC assessment 
were included. Blood draws and detailed surveys regarding 
symptoms and medical history were performed prior to 
MDCT scanning. Upon excluding patients undergoing 
any form of hemodialysis, 533 subjects were available for 
analysis. No other exclusion criteria were applied. The study 
was approved by the institutional review board at the authors’ 
institution, and informed consent was obtained from each 
participant.
Baseline characteristics collected included age, gender, 
weight, height, body mass index (BMI), self-identified ethnic-
ity (Caucasian, African-American, Hispanic/Latino, Asian, 
or Other), self-identified lifestyle (subjectively sedentary, 
active, or stressful), comorbid conditions (hyperlipidemia, 
hypertension, diabetes), current smoking status, current use 
of lipid lowering medications, and family history. Reported 
comorbidities were verified via physical exam, chart review, 
and laboratory data. Glomerular filtration rate (GFR) was 
calculated from serum creatinine drawn within 1 month 
prior to scanning using the simplified Modification of Diet 
in Renal Disease (MDRD) formula.14
MDcT protocol
All MDCT scans were performed at the center using a 
64-multidetector row Lightspeed VCT scanner (GE Health-
care, Little Chalfont, UK). Patients were given beta blockers 
as needed for a goal heart rate of ,60 bpm. The MDCT 
scanning protocol and interpretation methods for this study 
were identical to the authors’ core computed tomography 
(CT) reading laboratory function in the Multi-Ethnic Study 
of Atherosclerosis (MESA).15
Calcification was quantified as previously described by 
Agatston et al.16 Total coronary artery calcium score was 
calculated by the Agatston method as the sum of lesion scores 
from the four major coronary arteries (left main, left anterior 
descending, left circumflex, and right coronary  arteries). 
A single experienced interpreter, blinded to the GFR of the 
participant, interpreted all studies on commercially available 
software (AccuImage Workstation, AccuImage Diagnostics 
Corporation, San Mateo, CA) at the time of the study. CAC 
scores were not re-measured for the purposes of this study.
statistical analysis
Patients were divided into three groups: normal GFR 
(GFR .  90 mL/min/1.73 m2), mild CKD (90 $ 
GFR . 60 mL/min/1.73 m2), and moderate CKD (60 $ 
GFR . 30 mL/min/1.73 m2) based on the National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative 
practice guidelines for classification.17 Continuous variables 
and categorical variables were compared using analysis of 
variance and the χ2 statistic, respectively. A multiple logis-
tic regression model was used for detecting the association 
between total CAC score and GFR in the overall study 
population. An unadjusted model was used, followed by a 
second model adjusted for covariates known to be related 
to CAC, including age, gender, race, BMI, family history, 
hyperlipidemia, hypertension, diabetes, use of lipid-lowering 
medication, and current smoking status. The association 
analysis was performed on the full population, as well as 
gender subgroups. Since calcium scores have a nonnormal 
distribution, the median CAC scores are presented in the 
GFR subgroup comparison.
Another multivariable binary logistic model predicting 
presence of CAC (.10) was performed and odds of inci-
dence of CAC (.10) were calculated among the three GFR 
 subgroups. This analysis was performed on the full  population 
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Table 1 Clinical and demographic characteristics of study population stratified by glomerular filtration rate (GFR) (mL/min per 1.73 m2)
GFR . 90  
n = 240
90 $ GFR . 60  
n = 197
60 $ GFR . 30  
n = 96
P-value
Age (years) 55 ± 11 65 ± 9 74 ± 9 ,0.001
Men, n (%) 177 (73.8) 126 (64.0) 49 (51.0) ,0.001
Height (cm) 174.4 ± 11.0 170.5 ± 10.0 164.9 ± 11.8 ,0.001
Weight (kg) 93.3 ± 19.3 78.5 ± 14.3 67.2 ± 13.4 ,0.001
BMI (kg/m2) 30.7 ± 6.2 27.0 ± 4.2 24.7 ± 4.9 ,0.001
Ethnicity, n (%) ,0.001
caucasian 156 (65.0) 133 (67.5) 49 (51.0)
African-American 10 (4.2) 7 (3.6) 7 (7.3)
Hispanic/latino 60 (25.0) 33 (16.8) 17 (17.7)
Asian 14 (5.8) 22 (11.2) 21 (21.9)
Others 0 (0.0) 2 (0.9) 2 (2.1)
smoking status 30 (12.6) 12 (6.2) 5 (5.6) 0.03
Lifestyle, n (%) ,0.001
sedentary 34 (14.2) 33 (16.8) 29 (30.2)
Active 112 (46.7) 118 (60.2) 48 (50.0)
stressful 71 (29.6) 22 (11.2) 7 (7.3)
Others 23 (9.5) 23 (11.8) 12 (12.5)
Family history, n (%) 139 (59.9) 102 (53.4) 56 (61.5) 0.29
Hyperlipidemia, n (%) 133 (55.9) 127 (64.8) 57 (61.3) 0.16
Lipid lowering medication, n (%) 57 (25.0) 61 (31.9) 29 (32.2) 0.22
Hypertension, n (%) 100 (42.2) 95 (48.2) 60 (64.5) 0.001
Diabetes, n (%) 46 (19.2) 32 (16.3) 23 (25.0) 0.21
Total cAc score median 58 151 606 ,0.001
Abbreviation: cAc, coronary artery calcium.
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and gender subgroups as well. All data were exported to SAS 
(v 9.2; SAS Institute, Inc, Cary, NC) for analysis.
Results
A total of 533 participants were evaluated in the study after 
eleven subjects were excluded because they were currently 
undergoing hemodialysis. Of the 533, 240 had GFR in the 
normal range, 197 subjects had mild CKD, and 96 had mod-
erate CKD. There were significant differences between the 
groups in terms of gender (P , 0.001), race (P , 0.001), 
BMI (P , 0.001), lifestyle (P , 0.001), smoking status 
(P = 0.03), and incidence of hypertension (P = 0.001). The 
median CAC scores values among the GFR subgroups were 
58, 151, and 606, respectively. Patient demographic data can 
be found in Table 1.
In the unadjusted analysis, patients with mild CKD 
(90 $ GFR $ 60 mL/min/1.73 m2) had mean CAC scores 
174 points higher than those with the referent normal GFR 
(GFR . 90 mL/min/1.73 m2) (P = 0.03), while patients with 
moderate CKD (60 $ GFR . 30 mL/min/1.73 m2) had mean 
CAC scores 575 points higher than the referent (P , 0.001). The 
significance of these findings held up after adjustment for age, 
gender, race, BMI, hypertension, lifestyle, and smoking status. 
After adjustment, patients with mild CKD had mean CAC scores 
175 points higher than those with normal GFR (P = 0.048), while 
those with moderate CKD had mean CAC scores 693 points 
higher than the referent (P , 0.001). (See Table 2.)
When men were analyzed as a group, men with moderate 
CKD had mean CAC scores 834 points higher than those 
with normal GFR (P , 0.001) without adjustment. After 
adjustment for age, gender, race, BMI, hypertension, lifestyle, 
and smoking status, men with moderate CKD were found to 
have mean CAC scores 809 points higher than the referent 
(P , 0.001). Similarly, women with moderate CKD had mean 
CAC scores 441 points higher than those with normal GFR 
(P , 0.001) without adjustment. After adjustment for the 
factors just listed, women had mean CAC 544 points higher 
than those with normal GFR (P , 0.001). (See Table 2.)
Without adjustment, in the full population, patients with 
mild CKD were 1.9 times more likely to have incident CAC 
(defined as CAC score .10) (95% confidence interval [CI] 
1.3–2.9, P = 0.002), while patients with moderate CKD 
were 4.1 times more likely to have incident CAC when 
compared to the group with normal GFR (95% CI 2.3–7.8, 
P , 0.001). After adjustment for age, gender, race, BMI, 
hypertension, lifestyle, and smoking status, patients with 
mild CKD were found to be 2.2 times more likely (95% CI 
1.3–3.7, P = 0.004) and patients with moderate CKD were 
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6.4 times more likely (95% CI 2.9–14.3, P , 0.001) to have 
incident CAC compared with the referent group with normal 
GFR. (See Table 3.)
Without adjustment, men with moderate CKD were 
6.7 times more likely to have incident CAC (95% CI 
2.0–22.6, P = 0.002) compared to men with normal GFR. 
After adjustment for age, gender, race, BMI, hyperten-
sion, lifestyle, and smoking status, men with moderate 
CKD were 5.4 times more likely to have CAC (95% CI 
1.4–20.6, P = 0.02) compared with the referent. Women 
with moderate CKD were 6.4 times more likely (95% CI 
2.7–15.3, P , 0.001) to have CAC compared to women 
with normal GFR. After adjustment for age, gender, race, 
BMI, hypertension, lifestyle, and smoking status, women 
with moderate CKD were 6.6 times more likely (95% CI 
2.3–18.7, P , 0.001) to have CAC compared with the 
referent. (See Table 3.)
Discussion
CAC scores are a reliable screening tool for cardiovascular 
disease.18 CAC scores help predict both incidence of myocar-
dial infarction and death from cardiovascular disease.2 In a 
small cohort, Russo et al previously showed that patients with 
pre-dialysis CKD have an increased incidence of CAC19 and, 
in the Dallas Heart Study, Kramer et al showed an association 
between CKD stages 3–5 and increased CAC.20 Most recently, 
Table 2 Association between glomerular filtration rate (GFR) levels and coronary artery calcium (CAC) score in the full population 
and gender subgroups
Number of  
subjects
Total CACs  
median
Unadjusted CACs increase Adjusted CACs increasea
β (SE) 95% CI P-value β (SE) 95% CI P-value
Full population
 gFR . 90b 240 58 Referent Referent
 90 $ gFR . 60 197 151 174 (81) 16,333 0.03 175 (88) 2–347 0.048
 60 $ gFR . 30 96 606 575 (102) 376,774 ,0.001 693 (117) 464,922 ,0.001
Men
 gFR . 90b 177 105 Referent Referent
 90 $ gFR . 60 126 286 238 (106) 31,446 0.024 161 (119) –74,395 0.18
 60 $ gFR . 30 49 1230 834 (147) 547,1121 ,0.001 809 (171) 474,1144 ,0.001
Women
 gFR . 90b 63 0 Referent Referent
 90 $ gFR . 60 71 15 141 (103) –62,344 0.17 194 (114) –30,418 0.09
 60 $ gFR . 30 47 340 441 (115) 215,667 ,0.001 544 (136) 278,809 ,0.001
Notes: aAdjusted for age, gender, race, body mass index, hypertension, lifestyle and smoking status; breferent group.
Abbreviations: SE, standard error; CI, confidence interval.
Table 3 Odds ratios (ORs) for the incidence of coronary artery calcium (CAC) score (CACs .10) according to glomerular filtration 
rate (GFR) levels
Subjects, n Incidence of CAC, n (%) Unadjusted Adjusteda
OR 95% CI P-value OR 95% CI P-value
Full population
 gFR . 90b 240 146 (60.8) Referent (1.0) Referent (1.0)
 90 $ gFR . 60 197 147 (74.6) 1.9 1.3–2.9 0.002 2.2 1.3–3.7 0.004
 60 $ gFR . 30 96 83 (86.5) 4.1 2.3–7.8 ,0.001 6.4 2.9–14.3 ,0.001
Men
 gFR . 90b 177 123 (69.5) Referent (1.0) Referent (1.0)
 90 $ gFR . 60 126 110 (87.3) 3.0 1.6–5.6 ,0.001 2.3 1.1–4.8 0.03
 60 $ gFR .30 49 46 (93.9) 6.7 2.0–22.6 0.002 5.4 1.4–20.6 0.02
Women
 gFR . 90b 63 23 (36.5) Referent (1.0) Referent (1.0)
 90 $ gFR . 60 71 37 (52.1) 1.9 0.9–3.8 0.07 2.0 0.9–4.5 0.10
 60 $ gFR . 30 47 37 (78.7) 6.4 2.7–15.3 ,0.001 6.6 2.3–18.7 ,0.001
Notes: aAdjusted for age, gender, race, BMi, hypertension, lifestyle and smoking status; breferent group.
Abbreviation: CI, confidence interval.
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Budoff et al showed a graded relationship between the  severity 
of CKD and CAC.21 Haydar et al have further shown that CAC 
in CKD is a predictor of obstructive atherosclerosis.22
As far as the authors are aware, this present analysis is the 
first to show a significant association between both mild and 
moderate pre-dialysis CKD and increased mean CAC, as well 
as CAC incidence. The results are quite dramatic but come 
as no surprise given previous data showing that CKD is an 
independent risk factor for cardiovascular mortality.1 In the 
authors’ full cohort of patients, mild CKD independently 
predicted an average increase in CAC score of 175, while 
moderate CKD independently predicted an increase in CAC 
score of 693. Patients with a CAC score of 101–299 have an 
independent increase in relative risk of all-cause mortality 
of 4.5, while patients with a CAC score of 400–699 have an 
independent increase of 9.2.23 In this study’s male cohort, 
moderate CKD independently predicted an average increase 
in CAC score of 834. A CAC score of 834 alone puts any 
asymptomatic male younger than 75 years old in at least the 
seventieth percentile for CAC in his age group. In the female 
cohort, moderate CKD independently predicted an average 
CAC score increase of 544. A CAC score of 544 puts any 
asymptomatic female under the age of 75 years old in at least 
the eightieth percentile for her age group.24
Both the Multi-Ethnic Study of Atherosclerosis 
(MESA)25 and Framingham Offspring Study26 failed to 
demonstrate a similar independent correlation between 
CKD and CAC. Both these studies only compared 
patients with GFR $ 60 mL/min/1.73 m2 to patients with 
GFR # 60 mL/min/1.73 m2,  however. They did not do an 
analysis comparing patients categorized in three GFR catego-
ries as was done in the present study. Additionally, neither of 
these studies had a sufficiently large enough cohort of patients 
with CKD: only 9.9% of patients in the MESA cohort had 
moderate CKD and only 6.3% of the Framingham cohort 
had moderate CKD. The authors’ cohort had a robust 18.0% 
of patients with moderate CKD in addition to 37.0% with 
mild CKD, which explains why the present study showed 
a significant relationship between CKD and CAC whereas 
these other studies did not.
The authors’ findings provide more impetus that patients 
with even mild pre-dialysis CKD should be screened and treated 
more aggressively for heart disease than the average popula-
tion. This is particularly important in light of  studies which 
have shown that patients with heart disease and concomitant 
CKD are often treated less aggressively than those with 
normal kidney function.27,31-33 Additionally, there is evidence 
that more aggressive treatment in these patients does work. 
In a subanalysis of the Treating to New Targets study, Shepherd 
et al showed that more aggressive treatment with high-dose 
atorvastatin led to a cardiovascular risk reduction of 32% in 
patients with CKD.31 In the Study of Heart and Renal Protec-
tion trial, Baigent et al showed that lowering LDL cholesterol 
with simvastatin and ezitimibe reduced the incidence of major 
atherosclerotic adverse events in patients with CKD.32
Current guidelines say that the goal blood  pressure for 
patients with CKD is ,130/80,33 the goal LDL is ,100 mg/dL, 
and the goal triglycerides are ,200 mg/dL.28 These goals are 
largely not being met in clinical practice.29,30 Physicians must 
improve at controlling hypertension and hyperlipidemia, which 
are major risk factors for cardiovascular disease in patients 
with even mild CKD. Aggressive treatment to keep calcium 
and phosphorous levels within the normal range, as well as 
controlling anemia and diabetes, are important as well. While 
CKD will inherently accelerate heart disease in our patients, we 
as physicians must do a better job of slowing down this process 
so that our patients can live longer and healthier lives.
This paper’s major limitation is that it is based upon a 
single-center, retrospective study. In the future, it would be 
interesting to perform a prospective, randomized trial to see 
the impact that strict cardiovascular risk-factor management 
has on patient outcomes.
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